N,N-dimethyl-4-nitrobenzenemethanesulphonamide | 88918-70-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,N-dimethyl-4-nitrobenzenemethanesulphonamide
• 英文别名: 4-Nitro-N,N-dimethylbenzenemethanesulfonamide；4-Nitro-N,N-dimethylbenzenmethanesulfonamide；(4-nitro-phenyl)-methanesulfonic acid dimethylamide；(4-Nitro-phenyl)-methansulfonsaeure-dimethylamid；N,N-dimethyl-1-(4-nitrophenyl)methanesulfonamide
• CAS: 88918-70-1
• 化学式: C₉H₁₂N₂O₄S
• mdl: MFCD18426289
• 分子量: 244.271
• InChiKey: IGYMVHDFCJKCSQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  91.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N,N-dimethyl-4-nitrobenzenemethanesulphonamide 在 氢气 作用下， 以 甲醇 为溶剂， 生成 4-Amino-N,N-dimethylbenzenemethanesulphonamide
  参考文献：
  名称：

  [EN] TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS
  [FR] COMPOSÉS DE TÉTRAHYDROPYRIDO[3,4-D]PYRIMIDINES UTILISÉS EN TANT QU'INHIBITEURS DE HPK1

  摘要：

  Tetrahydropyrido[3,4-d]pyrimidine compounds are provided that are potent HPK1 inhibitors. The compounds are useful to treat or prevent cancer and/or inflammatory and/or autoimmune diseases or symptoms thereof in mammals, particularly humans. The compounds have a chemical structure of the general Formula (I), (II), (III), (IV) or (V) or enantiomers or diastereomers or mixtures thereof or pharmaceutically acceptable salts thereof.

  公开号：

  WO2023220541A1
• 作为产物：
  描述：

  4-硝基-α-甲苯磺酰氯 在 二甲胺 作用下， 以 氯仿 为溶剂， 生成 N,N-dimethyl-4-nitrobenzenemethanesulphonamide
  参考文献：
  名称：

  INDOLYLALKYL DERIVATIVES OF PYRIMIDINYLPIPERAZINE AND METABOLITES THEREOF FOR TREATMENT OF ANXIETY, DEPRESSION, AND SEXUAL DYSFUNCTION

  摘要：

  本发明涉及通过给予某些吡咯啉基吡咯嗪的衍生物或其代谢物来缓解、预防和治疗焦虑、抑郁和性功能障碍的方法。一种首选实施例的化学式如下：

  公开号：

  US20090281114A1

文献信息

• Indolylalkyl derivatives of pyrimidinylpiperazine for treating vascular
  申请人：Bristol-Myers Squibb Company

  公开号：US05300506A1

  公开（公告）日：1994-04-05

  A series of novel indol-3-ylalkyl derivatives of alkoxypyrimidinylpiperazines are disclosed as Formula I. ##STR1## These compounds are intended to be useful agents for alleviation of vascular headache on the basis of their potent affinity and agonist activity at 5-HT1D binding sites.

  一系列新颖的吲哚-3-基烷基衍生物的烷氧基嘧啶基哌嗪被披露为公式I。这些化合物旨在通过它们在5-HT1D结合位点的强亲和力和激动剂活性来缓解血管性头痛。
• Antimigraine 4-pyrimidinyl and pyridinyl derivatives of
  申请人：Bristol-Myers Squibb Company

  公开号：US05434154A1

  公开（公告）日：1995-07-18

  A series of novel alkoxypyridin-4-yl and alkoxypyrimidin-4-yl derivatives of indol-3-ylalkylpiperazines of Formula I are intended to be useful agents ##STR1## for alleviation of vascular headache on the basis of their potent affinity and agonist activity at 5-HT1D binding sites.

  一系列新颖的Formula I的吲哚-3-基烷基哌嗪的烷氧基吡啶-4-基和烷氧基吡啶-4-基衍生物旨在成为有用的药剂，用于缓解血管性头痛，基于它们在5-HT1D结合位点的强亲和力和激动剂活性。
• INHIBITORS OF PROTEIN KINASES
  申请人：Schauerte Heike

  公开号：US20100184780A1

  公开（公告）日：2010-07-22

  The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceuticals compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases. formula (I).

  本发明提供了新化合物。这些化合物可用作CDK5抑制剂，因此它们可以包含在用于治疗任何类型疼痛、炎症性疾病、免疫疾病、增殖性疾病、传染病、心血管疾病和神经退行性疾病的药物组合物中。公式（I）。
• Inhibitors of protein kinases
  申请人：Schauerte Heike

  公开号：US20080275063A1

  公开（公告）日：2008-11-06

  The present invention provides new compounds. The compounds are useful as CDK5 inhibitors, and accordingly they can be included in pharmaceutical compositions for treating any type of pain, inflammatory disorders, immunological diseases, proliferative diseases, infectious diseases, cardiovascular diseases and neurodegenerative diseases.

  本发明提供了新化合物。这些化合物可用作CDK5抑制剂，因此它们可以包含在药物组合物中，用于治疗任何类型的疼痛、炎症性疾病、免疫性疾病、增殖性疾病、传染病、心血管疾病和神经退行性疾病。
• Heterocyclic compounds
  申请人：Glaxo Group Limited

  公开号：US04816470A1

  公开（公告）日：1989-03-28

  Indole derivatives of the general formula (I) are disclosed: ##STR1## where R.sub.1 is H or an alkyl or alkenyl group, R.sub.2 is H, or an alkyl, alkenyl, aryl, aralkyl or cycloalkyl group; R.sub.3 is H or an alkyl group; R.sub.4 and R.sub.5 are independently H or an alkyl or propenyl group or together form an aralkylidene group; and Alk is an optionally substituted alkylene chain; and their physiologically acceptable salts and solutes. These compounds are potentially useful for the treatment of migraine and may be formulated as pharmaceutical compositions in conventional manner. Various methods for the production of the compounds are disclosed including a Fischer-indole cyclization process.

  公式(I)的吲哚衍生物被揭示：##STR1## 其中R.sub.1是H或烷基或烯基基团，R.sub.2是H或烷基，烯基，芳基，芳基烷基或环烷基；R.sub.3是H或烷基基团；R.sub.4和R.sub.5独立地是H或烷基或丙烯基基团，或一起形成芳基烷基亚胺基团；而Alk是一个可选的取代烷基链；以及它们的生理上可接受的盐和溶质。这些化合物可能有助于治疗偏头痛，并可以按照常规方式制成制药组合物。揭示了各种合成该化合物的方法，包括Fischer-吲哚环化反应。